| Title: |
Identification and Development of BRD9 Chemical Probes. |
| Authors: |
Colarusso, Ester1 (AUTHOR) ecolarusso@unisa.it, Chini, Maria Giovanna2 (AUTHOR) mariagiovanna.chini@unimol.it, Bifulco, Giuseppe1 (AUTHOR) bifulco@unisa.it, Lauro, Gianluigi1 (AUTHOR) glauro@unisa.it, Giordano, Assunta3 (AUTHOR) assunta.giordano@cnr.it |
| Source: |
Pharmaceuticals (14248247). Mar2024, Vol. 17 Issue 3, p392. 31p. |
| Subject Terms: |
*STRUCTURE-activity relationships, *DRUG discovery, *CARRIER proteins, *SMALL molecules, *GENE expression, *CHROMATIN-remodeling complexes |
| Abstract: |
The development of BRD9 inhibitors involves the design and synthesis of molecules that can specifically bind the BRD9 protein, interfering with the function of the chromatin-remodeling complex ncBAF, with the main advantage of modulating gene expression and controlling cellular processes. Here, we summarize the work conducted over the past 10 years to find new BRD9 binders, with an emphasis on their structure–activity relationships, efficacies, and selectivities in preliminary studies. BRD9 is expressed in a variety of cancer forms, hence, its inhibition holds particular significance in cancer research. However, it is crucial to note that the expanding research in the field, particularly in the development of new degraders, may uncover new therapeutic potentials. [ABSTRACT FROM AUTHOR] |
|
Copyright of Pharmaceuticals (14248247) is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Academic Search Complete |
|
Full text is not displayed to guests. |
Login for full access.
|
